These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date 2007-003058-26 Pilot study on tolerability of specific immunotherapywith injective allergoid adsorbed on calcium phosphate in patients with respiratory allergy to house dust mite. bad-data
Completed, but no date 2008-007657-12 Evaluating the efficacy, safety, tolerability of use and treatment adherence in two different dosing schedules, pre-costagionale and costagionale, of a sublingual allergoid (Lais Parietaria)administer... bad-data
Completed, but no date 2009-013923-43 Studio in doppio cieco controllato con placebo sulla efficacia e tollerabilita' della terapia desensibilizzante con nichel in pazienti affetti da sindrome sistemica da allergia al nichel bad-data
Completed, but no date 2011-002174-23 A dose Finding Study of the Efficacy of LAIS Grass tablets in patients suffering from grass pollen-induced allergic rhinoconjunctivitis bad-data
Completed, but no date 2011-004522-10 Study on the efficacy and safety of three different doses of Lais Ambrosia tablets in patients with allergic rhinoconjunctivitis to pollen of Ambrosia bad-data
Completed, but no date 2012-001651-39 In-vivo biological standardization of Dermatophagoides, Betulaceae and Graminaceae extracts for the determination of the biological activity in HEP units bad-data
Not reported 2012-001822-89 A Dose Finding Study of the Efficacy of LAIS® Birch-Alder tablets in patients suffering from tree pollen-induced allergic rhinoconjunctivitis 2013-01-10 due-trials
Not reported 2012-004916-79 Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS® Grass tablets for patients with grass pollen-induced allergic rhinoconjunctivitis, a phase III study 2014-09-26 due-trials
Not reported 2013-000617-20 A Dose Finding Study of the Efficacy of LAIS® Mites Sublingual tablets in patients suffering from house dust mite-induced allergic rhinoconjunctivitis A prospective, double-blind, placebo-controlled r... 2014-05-09 due-trials
Not reported 2013-002129-43 Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS®Birch-Alder tablets for patients with tree pollen-induced allergic rhinoconjunctivitis A Phase III study 2014-07-29 due-trials
Ongoing 2014-004431-38 Double-blind, placebo-controlled, parallel-group, randomized multicentre study to assess the efficacy and safety of LAIS® Ragweed Sublingual tablet in patients with allergic rhinoconjunctivitis to rag... not-yet-due
Ongoing 2016-003439-39 A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergi... not-yet-due
Completed, but no date 2017-003063-34 A double-blind, placebo-controlled dose-escalation study of carbamylated monomeric tree pollen drops in patients with a history of allergic rhinoconjunctivitis. bad-data
Ongoing 2017-005079-21 A Prospective, Multicenter, Double-Blind, Placebo-Controlled, Dose-Finding Phase-II Study for the Efficacy and Safety of LAIS® House Dust Mites Sublingual Tablets in Patients with Mite-Induced Allergi... not-yet-due
Ongoing 2018-002596-18 Efficacy and Safety of sublingual immunotherapy with Allergoid LAIS Birch tablets for patients with tree pollen-induced allergic rhinoconjunctivitis with or without mild controlled asthma not-yet-due